Menu

TS Picks: October 24, 2016

Theranos’s bad blood tests; presidential science lessons; “three-parent” babies

Oct 24, 2016
Tracy Vence

PUBLIC DOMAIN PICTURES, CIRCE DENYER

Selections from The Scientist’s reading list

  • The Wall Street Journal spoke with patients who were affected by inaccurate Theranos blood tests. “Rattled patients who told The Wall Street Journal they sought more information about their results said they got no response, and weeks or months passed before Theranos told many patients that their results were unreliable.” The Wall Street Journal also reviewed an undisclosed report from the US Centers for Medicare and Medicaid Services, which found that 834 of 2,890 quality-control checks using the company’s proprietary Edison devices “exceeded the company’s threshold of two standard deviations from its average result,” the publication reported.

See “Theranos Restructuring with Research Focus

See “Theranos CEO Banned from Running Labs for Two Years

  • Science last week (October 20) offered “science lessons for the next president,” including backgrounders on evolving pathogens and applications of CRISPR.
     
  • Last month, New Scientist reported on the birth of the first baby to have been treated with mitochondrial replacement therapy (MRT). Now, “that ‘three-parent’ baby may soon have company—if it does not already,” Nature reported last week (October 29). “Numerous scientific groups and government agencies are debating whether the procedure should be allowed in clinical use. Most conclude that mitochondrial replacement should be performed only under the auspices of a clinical trial and with independent oversight.”

See “First MRT Baby Born

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.